- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05061823
Bintrafusp Alfa Program Rollover Study
An Open-label, Multicenter Follow-up Study to Collect Long-term Data on Participants From Multiple Bintrafusp Alfa (M7824) Clinical Studies
This study is designed to provide continuous access to treatment with bintrafusp alfa for eligible participants from ongoing bintrafusp alfa parent studies (NCT02517398, NCT03840902, NCT02699515, NCT04246489, NCT04489940, NCT03840915, NCT03631706, NCT04551950, NCT03833661 and NCT04066491) and to collect long-term safety and efficacy data.
Study Duration: All participants in this rollover study will be treated with bintrafusp alfa until meeting defined criteria in the protocol for discontinuation, until study intervention is commercially accessible and provisioned via marketed product, or until end of study.
The study also includes a 5 years survival follow-up after last dose of the study treatment.
Treatment Duration: Treatment under the rollover protocol according to the interval and dosing schedule in the parent protocol until discontinuation.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Libramont, Belgium
- Centre Hospitalier de l'Ardenne - PARENT
-
-
-
-
-
Harbin, China
- Harbin Medical University Cancer Hospital
-
-
-
-
-
Dresden, Germany
- Universitaetsklinikum Carl Gustav Carus TU Dresden - Medizinische Klinik I
-
-
-
-
-
Lazio, Italy
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS - UOC Oncologia Medica
-
-
-
-
-
Chuo-ku, Japan
- National Cancer Center Hospital
-
Hidaka-shi, Japan
- Saitama Medical University International Medical Center
-
Kashiwa-shi, Japan
- National Cancer Center Hospital East
-
-
-
-
-
Incheon, Korea, Republic of
- Gachon University Gil Medical Center
-
Seoul, Korea, Republic of
- Seoul National University Hospital
-
Seoul, Korea, Republic of
- Asan Medical Center
-
Seoul, Korea, Republic of
- Severance Hospital, Yonsei University Health System
-
-
-
-
-
Omsk, Russian Federation
- BHI of Omsk region "Clinical Oncology Dispensary" - PARENT
-
-
-
-
-
Madrid, Spain
- Hospital General Universitario Gregorio Maranon
-
Madrid, Spain
- Hospital Universitario Ramon y Cajal - Servicio de Oncologia
-
Valencia, Spain
- Hospital Clinico Universitario de Valencia - Servicio de Hematologia y Oncologia Medica
-
-
-
-
-
Taichung, Taiwan
- Taichung Veterans General Hospital
-
Taoyuan County, Taiwan
- Chang Gung Memorial Hospital,Linkou
-
-
-
-
-
Adana, Turkey
- Adana City Hospital - Parent Account
-
-
-
-
-
Lutsk, Ukraine
- Communal Enterprise Volyn Regional Medical Center of Oncology of Volyn Regional Council - Department of Oncochemotherapy
-
-
-
-
Maryland
-
Bethesda, Maryland, United States, 20817
- The Center for Cancer and Blood Disorders a Division of American Oncology Partners of Maryland, P.A.
-
Bethesda, Maryland, United States, 20892
- NIH National Institutes of Health/GMB LTIB
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Participants who are currently enrolled in an eligible bintrafusp alfa parent study where the primary/main analysis has been completed or after discontinuation of study before primary/main analysis has been completed or after discontinuation of study before primary/main analysis has been completed
- Participants who are currently on active bintrafusp alfa treatment alone as a monotherapy or following discontinuation of other combination treatment agents in the parent study and without treatment interruption at the time of rollover study enrollment
- Participants who experienced a confirmed complete response (CR), partial response (PR), or stable disease (SD) in an eligible parent study, discontinued bintrafusp alfa treatment according to the parent study protocol, and subsequently developed disease progression and are willing to re-start bintrafusp alfa treatment deemed potentially beneficial by the participants' physicians
- Participants who are.discontinued from bintrafusp alfa treatment in an eligible parent study due to an adverse events (AEs) that was subsequently well controlled or completely resolved after stopping therapy, provided that the parent study protocol permits reinitiation of bintrafusp alfa if a participant discontinued treatment due to toxicity and these participants are willing to re-start bintrafusp alfa treatment deemed potentially beneficial by the participants' physicians. Participants who have had AEs requiring permanent treatment discontinuation, like certain immune-related adverse events (irAEs) or certain bleeding events are excluded from participation in this Rollover study
- Participants with only SD at the time of discontinuation, the Investigator should confirm that no other reasonable treatment options are available
- Participants who have completed End of treatment (EoT) assessment of a parent study
- The investigator confirms that each participant agrees to use appropriate contraception and barriers, if applicable. The contraception, barrier, and pregnancy testing requirements are below:
- For female participants of childbearing potential or for male participants who have female partners of childbearing potential, the following applies:
- Participants on active treatment must agree to continue to use highly effective contraception for both male and female participants if the risk of conception exists thus, women of childbearing potential and men must agree to use highly effective contraception as stipulated in national or local guidelines
- Highly effective contraception must be used 28 days prior to the first study intervention administration, for the duration of study intervention, and at least for 2 months (for female participants) or 4 months (for male participants) after stopping study intervention
- Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, the treating physician should be informed immediately
Exclusion Criteria:
- Participants who are pregnant or currently in lactation
- Participants with known hypersensitivity to any of the study intervention ingredients.
- Participants reinitiating treatment with bintrafusp alfa at study entry: have received any systemic anticancer therapies/treatments since discontinuing bintrafusp alfa treatment.
- Participants who has withdrawn consent from the parent study for any reason
- Any other reason that, in the opinion of the Investigator, precludes the participant from participating in the study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Bintrafusp alfa
|
Participants who are continuing treatment with bintrafusp alfa and were previously assigned to a bintrafusp alfa dose based on body weight which is (i.e.) milligrams per kilogram (mg/kg) per dose in a parent protocol, will receive an intravenous infusion of bintrafusp alfa at the dose specified based upon the participant's parent protocol once every 2 week or, 2400 mg once every 3 weeks.
Participants who are entering the rollover study after discontinuation of treatment in a parent study will receive bintrafusp alfa at a dose of either 1200 or 2400 mg once every 2 weeks or 2400 mg once every 3 weeks until confirmed disease progression, death, unacceptable toxicity or study withdrawal.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Occurrence of Adverse Events and Treatment-Related Adverse Events
Time Frame: Time from first treatment in parent study to planned final assessment at approximately up to 5 years
|
Time from first treatment in parent study to planned final assessment at approximately up to 5 years
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Overall Survival (OS)
Time Frame: Time from first treatment in parent study to planned final assessment at approximately up to 5 years
|
Time from first treatment in parent study to planned final assessment at approximately up to 5 years
|
Collaborators and Investigators
Collaborators
Investigators
- Study Director: Medical Responsible, Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- MS200647_0054
- 2021-000179-36 (EudraCT Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- ANALYTIC_CODE
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cancer
-
University of Michigan Rogel Cancer CenterRecruitingCancer Liver | Cancer Brain | Cancer Head &Neck | Cancer PelvisUnited States
-
Cellworks Group Inc.RecruitingCancer | Relapsed Cancer | Refractory CancerUnited States
-
Vanderbilt-Ingram Cancer CenterNational Institutes of Health (NIH)Active, not recruitingAdvanced Cancer | Relapsed Cancer | Refractory CancerUnited States
-
UNC Lineberger Comprehensive Cancer CenterHyundai Hope On WheelsRecruitingCancer | Pediatric Cancer | Survivorship | Cancer MetastaticUnited States
-
MiRXES Pte LtdRecruitingBreast Cancer | Gastric Cancer | Colorectal Cancer | Pancreatic Cancer | Esophageal Cancer | Ovarian Cancer | Prostate Cancer | Thoracic Cancer | Liver CancerSingapore
-
Sidney Kimmel Cancer Center at Thomas Jefferson...CompletedStage I Breast Cancer | Stage I Uterine Corpus Cancer | Stage II Uterine Corpus Cancer | Stage III Uterine Corpus Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage... and other conditionsUnited States
-
Massachusetts General HospitalNational Comprehensive Cancer NetworkCompletedGastric Cancer | Pancreatic Cancer | Esophageal Cancer | Rectal Cancer | Colon Cancer | Hepatobiliary CancerUnited States
-
Johns Hopkins UniversityNational Cancer Institute (NCI); National Institute on Minority Health and...Enrolling by invitationCancer | Advanced Cancer | End Stage Cancer | MalignancyUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)CompletedStage III Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IV Gastric Cancer | Stage IVA Colorectal Cancer | Stage IVA Pancreatic Cancer | Stage IVB Colorectal Cancer | Stage IVB Pancreatic Cancer | Stage IIIA Gastric Cancer | Stage IIIB Gastric Cancer | Stage IIIC Gastric... and other conditionsUnited States
-
Case Comprehensive Cancer CenterCompletedStage IIA Rectal Cancer | Stage IIB Rectal Cancer | Stage IIC Rectal Cancer | Stage IIIA Rectal Cancer | Stage IIIB Rectal Cancer | Stage IIIC Rectal Cancer | Stage IIIA Colon Cancer | Stage IIIB Colon Cancer | Stage IIIC Colon Cancer | Recurrent Colon Cancer | Recurrent Rectal Cancer | Stage IVA Colon Cancer | Stage IVA Rectal Cancer and other conditionsUnited States
Clinical Trials on Bintrafusp alfa
-
The University of Hong KongMerck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt...Active, not recruitingNasopharyngeal Carcinoma | Metastatic Cancer | Recurrent Carcinoma | Non-keratinizing CarinomaHong Kong
-
Queen Mary University of LondonNot yet recruitingTransitional Cell Carcinoma | Bladder Cancer
-
GlaxoSmithKlineMerck KGaA, Darmstadt, GermanyTerminatedNeoplasmsSpain, United States, France, Netherlands, Canada
-
National Cancer Institute (NCI)Active, not recruitingOlfactory Neuroblastoma | Esthesioneuroblastoma | Neoplasm of the Nasal CavityUnited States
-
AIO-Studien-gGmbHMerck Serono GmbH, GermanyTerminatedCholangiocarcinoma | Biliary Tract CancerGermany
-
National Cancer Institute (NCI)TerminatedUrothelial CancerUnited States
-
UNICANCERMerck KGaA, Darmstadt, GermanyTerminatedSquamous Cell Carcinoma of Head and NeckFrance
-
EMD Serono Research & Development Institute, Inc.Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt...TerminatedTriple Negative Breast NeoplasmsUnited States, France, Belgium, Spain, Russian Federation, Italy
-
EMD Serono Research & Development Institute, Inc.Merck KGaA, Darmstadt, GermanyCompletedCholangiocarcinoma | Biliary Tract Cancer | Gallbladder CancerKorea, Republic of, United States, Taiwan, Italy, France, China, Japan, Spain, United Kingdom
-
Fundación GECPRecruiting